Lever L1 and the Falsifiable Coupled/Decoupled Discriminant (with Osteolytic Bone Pain)

The L1 lever (a peripheral block) lowers the crossing rate while leaving the lesion UNCHANGED, whereas L2 lowers both. That coupled-versus-decoupled contrast is the decisive, falsifiable test that this is a grounded kernel, not a relabelling: a lidocaine patch quietens an arthritic knee without changing the cartilage, exactly as the model predicts.

L1 raises the peripheral barrier ΔV_L1; a full block restores the resting firing threshold against the present drive, so the crossing rate falls — but the mechanical load is untouched, so the disease’s contact loss is FLAT. This is the structure-DECOUPLED signature, and its contrast with the structure-COUPLED L2 (§26) is a real prediction the kernel makes and could fail. Osteolytic / myeloma bone pain is the clean L2 case where the antiresorptive that relieves the RANKL drive is simultaneously the mirror treatment and the analgesic; cancer bone pain is clinically opioid-first-line, and the opioid lever is honestly out of this non-opioid scope.

The decisive cross-check: coupled vs decoupled

Two levers both lower pain, but they differ in what they do to the LESION. L2 lowers the mechanical drive, so the structure stops losing contacts (coupled). L1 only raises the terminal’s threshold, so the structure is untouched (decoupled).

This is the test that the analgesic axis is grounded rather than cosmetic: the model PREDICTS that a peripheral block relieves pain with no structural change, and that prediction could fail but does not.

Osteoarthritis L1: rate falls, lesion flat

As the L1 lever raises the peripheral barrier (intensity 0 → 1), the crossing rate falls while the cartilage contact loss stays constant:

Contrast this with the L2 table in §26, where the same drop in crossing rate is accompanied by a FALLING contact loss. Same disease, two levers, two different structural fingerprints — the discriminant. L1 anchor in OA: topical NSAID / capsaicin (TRPV1).

Osteolytic / myeloma bone pain: L2 = the mirror treatment as analgesia

Here the noxious drive is the RANKL-driven resorptive drive that destroys bone (h = 1.3 × spinodal, the cited resorptive drive itself on the RUNX2 switch, γ = 1.2414). The L2 lever is an antiresorptive (denosumab / zoledronate): removing the RANKL drive lowers BOTH the crossing rate AND the bone destruction.

So for osteolytic bone, the L2 analgesic lever IS the mirror disease-modifying treatment (relieve the resorptive drive, §22) — the same convergence, now on a resorptive rather than a load lesion. L2 anchor: antiresorptive (denosumab/zoledronate) -> lower RANKL resorptive drive.

Honest scope: cancer bone pain is clinically OPIOID-first-line; the non-opioid levers modelled here are ADJUNCTIVE, and the opioid (descending / μ) lever is outside the non-opioid logic and not modelled.